Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

August 9, 2021

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 47 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being with us today as we go over Penumbra's results for Q2 2021. You can find the press release along with the financial tables—those contain reconciliations from GAAP to non-GAAP—by visiting the Investors section of our site, www.penumbrainc.com. On this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, and those cover things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality compliance, and business trends. Because of various risks and uncertainties—among them the ones described in our 10-K covering the year that ended December 31, 2020, which we filed with the SEC—actual outcomes may differ materially from what those forward-looking statements state or suggest. So we urge you not to place excessive reliance on them, and we suggest you look at our periodic SEC filings, including that 10-K, to get a fuller picture of these factors and other risks that could impact our future results or the market price of our stock, such as, though not limited to, how the COVID-19 pandemic affects our business, results of operations and financial conditions. Penumbra accepts no obligation to update or revise these forward-looking statements because of new information, future events, developments, or anything else. Some financial measures on this call are presented on a non-GAAP basis, and a reconciliation between GAAP and non-GAAP financial measures appears in the press release we posted. We expect the prepared remarks today to take roughly 18 minutes. Adam Elsesser, who serves as Penumbra's Chairman and CEO, will give a business update. After that, Maggie Yuen, our Chief Financial Officer, will go through our financial results for the second quarter; and Jason Mills, our Executive Vice President of Strategy, will cover our updated 2021 guidance; and now I'd like to hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Jee, and welcome back from maternity leave. Good afternoon, everyone. We appreciate you joining Penumbra's Second Quarter 2021 Conference Call. For Q2, our total revenues came to $184.3 million — that's up 75.3% year over year as reported, 72.7% in constant currency, and a 9% sequential gain over the prior quarter. During the second quarter of 2021, operating income was $10.3 million, or 6% of revenue, versus an operating loss of $18 million in the same period a year ago. Both our Vascular and Neuro businesses turned in solid results this quarter, fueled by how broad and robust our product portfolios are, hard work from our excellent sales teams, and a rise in elective procedures probably tied to two things: increasing COVID vaccination rates in certain locations and a buildup of deferred elective cases. Naturally, we're watching the current headlines closely regarding the Delta variant's spread. That said, we aren't experiencing any negative effect on the business overall, and we think any impact down the road would look no different from what others in this industry face. On the whole, despite what we're reading in the news, we feel good about our capacity to serve more and more patients, and we keep finding plenty of opportunities in our target markets to fuel strong, durable growth in the years ahead. Also, we keep seeing a powerful symbiosis between our thrombectomy and embolization franchises across both Neuro and Vascular, where purposeful innovation in one area strengthens our position in both. On top of that, we're bringing excellent new people onto the Penumbra team, in our commercial organization and within our senior leadership team alike. Let me begin with our Vascular business. In the second quarter, we posted growth of 117.6% year over year, reaching $100.7 million. We're doing significant work in four key areas where patients have needs: arterial, venous, coronary, and embolization. The reason we're growing is that physicians are increasingly embracing what our products can offer in each of those spaces, as more of them learn how our advanced therapies can help the people they treat. Lightning 7, which we recently introduced for arterial anatomy, has done remarkably well, and it follows the momentum we've built with Lightning 12 in venous anatomy since that product came out a year ago. We saw strong growth from both doctors who were already customers and those who are new, using our catheters for arterial thrombectomy, and much of that is due to how quickly Lightning 7 has taken off. When you put it all together, there's still a huge chance for us to expand our footprint in arterial and venous going forward. The Lightning technology — now an essential piece of both arterial and venous — is being received very positively by physicians, a growing number of whom are turning to single-session therapy because of the benefits for patient outcomes and the lower cost to the health care system. For those of you who follow us, you're aware that we're conducting clinical trials involving PE — both the venous and arterial vasculature — using Lightning, so we can gain further knowledge and better inform our customers about what it offers. There's still considerable ground to cover before Lightning reaches every patient who might benefit. Our estimate is that roughly 90% of the eligible individuals suffering from venous or arterial clots are not — continue not to be — receiving single-session therapy; we keep putting resources into therapy development programs and clinical evidence so these vital products can reach more people. Remaining within the Vascular franchise, our coronary thrombectomy business and our peripheral embolization business each posted record quarters in Q2. Through CAT RX, our footprint in the coronary thrombectomy market keeps expanding, and we're still funding key clinical efforts aimed at broadening use of this one-of-a-kind product. For example, fresh data shared at ACC 2021 back in May underscored the safety and efficacy of CAT RX among patients carrying a high thrombus burden in the coronaries; that research is helping us build momentum with CAT RX at academic institutions as well as high-volume ones. Turning to embolization, we observed a rise in elective procedures throughout the second quarter as COVID-19 vaccinations picked up across the U.S. in the spring, which in all likelihood allowed hospitals to increase their procedure volumes. Considering where vaccinations stand now and how new variants of the virus are spreading, it's possible that this bump in elective cases settles somewhat during the third quarter; even so, we anticipate that growth trends will persist in this business — not only within the United States, but across international markets too, over the long haul. All told, each of our 4 Vascular franchises is fueling robust growth in our Vascular business, steered by the breadth of our portfolio and deliberate innovation; we keep identifying numerous appealing chances for ongoing expansion and investment in our people, products, clinical studies and markets as we move ahead. Now let me discuss our Neuro business, which likewise turned in a solid second quarter. Globally, our Neuro sales came in at $83.6 million, which is up 42% compared with the same period last year. I couldn't be prouder of the Neuro group for what they've accomplished over the past few quarters, even with a recall on one product and tough competition in the market. Still, looking ahead, we see a lot of promise across stroke, access, embolization, and neurosurgical. Early procedures with the RED 62, our new distal stroke catheter, have performed very well. Physicians we work with have really welcomed how much more easily this strong catheter can be navigated into distal anatomy. As we keep broadening RED 62's footprint in the months ahead, we're thrilled to also bring out the RED 68 catheter, which just secured FDA clearance, plus a third catheter within the RED series that we anticipate clearing later this quarter; we can't wait for all 3 of these new offerings to be in the hands of our physician customers for treating their stroke patients. Also, the scope of our Neuro lineup stood out once more during this quarter. Record quarters were posted by both our embolization portfolio and our neuro access portfolio. BMX96, introduced late last year, keeps experiencing greater adoption and utilization throughout the neuro interventional field. Overall, our neuro division continues to build considerable momentum, driven by the exact foundational principles that made this group and franchise the best in the world for years: a focus on innovation that delivers improved patient results, along with a broad portfolio of unique offerings that help the physicians we serve treat more people successfully. Our Neuro team is motivated, involved, and prepared to perform, and our innovation pipeline is functioning extremely well. We're eager to share details soon about THUNDERBOLT, our new paradigm in stroke intervention. Moving on to the virtual reality side of things, the REAL VR platform has come a long way, and we're more and more hopeful that this in-house technology could be of benefit to millions of patients dealing with a wide range of clinical and cognitive health conditions. Serving so many different patient populations across all sorts of care environments requires a handful of key elements. Number one, VR technology we own that gives patients a completely immersive experience they can take with them. Number two, a platform flexible enough to work in many different care settings. Number three, a VR experience tailored to what patients need in each of those settings. Fourth, we need a content library that’s rich, purposeful, and engaging—one built to serve patients across various environments and with varying health care requirements. With that in mind, the REAL system will come in 3 hardware setups: the i-series, the t-Series, and the y-Series. Of these, the y-Series is a newer version of what we currently offer. At the HIMSS meeting this week, the i-Series will make its public debut. The advancements we've made in all those areas have us really enthusiastic—particularly given the support from our amazing partners at Sixense—and we're eager to work hand in hand with a strong VR community in therapeutic health care, using the REAL VR platform to benefit a large number of patients in the months and years ahead. On Tuesday, September 21, we plan to hold an Investor Meeting focused solely on our REAL VR franchise at Penumbra's campus in Alameda, California. We'll share specifics soon, and those plans will naturally depend on local regulations for in-person gatherings, which could shift; we hope everyone can attend. Now, moving on to news about our international business. The second quarter brought encouraging expansion across multiple areas. We achieved meaningful advances in China, Japan, Europe, and Canada, and we still see further chances to build our business in those regions as well as elsewhere, such as Latin America and Asia Pacific, looking ahead a few years. Our intention is to broaden what we offer in neuro and vascular across numerous markets abroad, while REAL VR stands as a more distant but promising prospect for growth beyond the United States. That wraps up that portion. Now I'll pass it over to Maggie, who will take us through the financials for the quarter.

Maggie Yuen

executive
#3

Thanks, Adam. Good afternoon to all of you. During this call, I'll go over the financial results for the second quarter of 2021. Our quarterly report on Form 10-Q will hold further specifics. Total revenues for the second quarter, which ended June 30, 2021, came to $184.3 million — that's growth of 75.3% as reported and 72.7% on a constant currency basis versus the second quarter of 2020. Sales in the quarter broke down geographically as 69.7% U.S. and 30.3% international. Compared with the same period in 2020, U.S. and international growth came in at 64.5% and 106.4%, respectively. Turning to revenue by franchise. In the second quarter of 2021, revenue from our Vascular business rose to $100.7 million, up 117.6% as reported and 115.8% in constant currency versus the same period a year ago. Versus the prior quarter, revenue from our Vascular business was up 12.9%, powered by strong peripheral thrombectomy performance and higher embolization procedure volume in the U.S. Revenue from our Neuro business reached $83.6 million in the second quarter of 2021, up 42% as reported and 38.8% in constant currency versus the same period a year ago. Against our performance in this period last year, when COVID-19 weighed on results, we see meaningful growth across the neuro access, embolization and neurothrombectomy businesses, along with growth in every region. I'm happy to say that, compared with the prior quarter, all international regions grew sequentially. Gross margin for the second quarter came in at 64.4%, versus 61.8% in last year's same quarter, on volume leverage, and we keep investing in resources to meet demand and support new product launches in the second half of 2021. As we look at the rest of this year, we anticipate our gross margin will normalize to roughly the same levels seen in the first 6 months of the year. Operating expense totaled $108.4 million for the quarter, or 59% of revenue, versus $82.6 million, or 79% of revenue, in last year's same quarter. Our research and development expenses for Q2 2021 came to $17.7 million, versus $22.7 million for Q2 2020. We expect R&D investment to pick up in the second half of 2021 for new product launches and THUNDERBOLT. SG&A expenses for Q2 2021 were $90.6 million, versus $59.9 million for Q2 2020. In the prior year, during this quarter, we had temporary cost reduction measures, including executive salary reductions, while we keep investing in commercial resources to support rising demand for our products. On top of that, most domestic travel and other in-person activities are going back to 2019 levels. For the second quarter of 2021, we recorded operating income of $10.3 million, or 6% of revenue, versus an operating loss of $17.6 million in last year's same period. We closed the second quarter with cash, cash equivalents and marketable security balance of $239 million at steady working capital. And now, I'd like to hand the call over to Jason to discuss our 2021 guidance.

Jason Mills

executive
#4

Thanks, Maggie, and good afternoon, everyone. Along with the update on our second quarter results, we're officially raising the range we're giving for 2021 revenue to $720 million to $730 million, and that would mean growth of 28% to 30% compared with 2020 revenue of $560.4 million. This revised guidance is up against the range we previously gave for 2021, $695 million to $705 million, which we provided on our first quarter call in May. We're seeing several things driving growth from here, so we expect total revenue to be higher in the second half of the year than it was in the first half. We're looking for strong growth in the third quarter versus the same period a year ago, when we had one of our best product launches ever in Lightning 12. Sequentially, we expect third quarter revenue to come close to our strong second quarter results as we factor in the mix dynamics of the current environment. Looking further out to the fourth quarter, we're expecting solid sequential growth from continued strong trends in our Vascular business, plus a growing contribution from new products in Neuro, specifically the RED series of catheters for stroke intervention. Overall, in line with how we've approached setting guidance before, our revised 2021 revenue guidance reflects our current views on our markets, the timing of new product launches and other relevant inputs. I'll now hand the call back to Adam for closing remarks.

Adam Elsesser

executive
#5

Thanks, Jason, Maggie, and Jee. The last 1.5 years have delivered enormous difficulties and grief beyond words across the globe. Even so, it has also revealed just how much resilience we all possess, particularly given the steady stream of shifting developments. With those thoughts in mind, the remarkable people at Penumbra, year in and year out, keep examining places where individuals endure medical problems and strive to develop fresh answers that improve their situation. That determination has been — has not been more apparent — has been more apparent over this last 1.5 years than at any earlier point. And that is why we sit in such a strong position to assist growing numbers of people in the coming months and years. I want to express gratitude to each member of the Penumbra team for accomplishing so much on behalf of so many. Thanks for listening. And at this point, I'd like to turn the call over for questions. Operator, please go ahead.

Bob Hopkins

analyst
#6

Congrats on an amazing quarter. I've got just a couple of fast questions. To start, regarding the pipeline, and those updates are quite good. I'm just wondering about THUNDERBOLT — could you tell us when we might hear more regarding that product? And then about REAL, I'm glad it's being presented at a meeting this week, but perhaps you could tell us when it will be — when this newest version will fully launch?

Adam Elsesser

executive
#7

Yes, Bob, those are excellent questions, and I appreciate your remarks. When it comes to THUNDERBOLT, I give you my word that we'll inform you the moment we're able. Clearly, we don't always have control over all of that schedule, but we'll do it the moment we're able. And clearly, you know I'm eager to pass along whatever I can whenever it becomes possible, so keep watching. We'll tell you folks the moment we're able. When it comes to REAL, we're putting it out in its very earliest phases and displaying it at this clearly significant conference, the HIMSS conference alongside the health care community; we'll bring you all up to date at the Investor Day on September 21 with far more specifics about timing and, well, how that entire picture — how the business — looks. I mean, I believe it will be far clearer once the Investor Day has happened.

Bob Hopkins

analyst
#8

All right, so essentially, keep watching for more.

Adam Elsesser

executive
#9

Though I put it in a pleasant way.

Bob Hopkins

analyst
#10

You did, as you always do. Turning to the Vascular area, and particularly chemical thrombectomy, I was hoping you might share a bit more about those outstanding results; you have arterial, venous, and coronary here. Could you tell us whether arterial still accounts for more than 50% of that business? And is every one of these indications expanding at a faster pace? Or do we see genuine divergence in growth rates across those 3?

Adam Elsesser

executive
#11

Yes, that's a great question. All of the growth rates are strong. Do they shift somewhat depending on our product launch? Of course, they do. We clearly saw Lightning 12 take a significant trajectory when we launched it. Lightning 7 has performed well. But every one of the franchises is doing well, and I'm very, very optimistic about how they will all contribute to our growth as we continue on.

Bob Hopkins

analyst
#12

Does arterial still account for more than 50%?

Adam Elsesser

executive
#13

Those figures haven't been split out in that way, as far as I know, but...

Jason Mills

executive
#14

Correct, Bob — this is Jason speaking, and we haven't provided those figures in that kind of detail. In previous comments we've noted that the venous portion has clearly risen substantially ever since Lightning 12 came to market. That trend is still going: at this point both the venous and arterial segments are performing strongly. So we won't split out those particular figures. I will mention, however, that penetration rates are quite comparable across those 2 categories. Naturally, we believe roughly 90% of the eligible patient groups that either product — and either category — could serve are candidates for single-session therapy. I realize we've made this point before, yet I think it deserves repeating for everyone.

Larry Biegelsen

analyst
#15

I'd like to add my congratulations to Bob's. First, Adam, regarding the COVID patterns and the guidance for the back half, and second, on vascular embolization, which came in quite strong this quarter. So to start with the recovery, I caught your prepared comments. It sounds like things are so far, so good, Adam, when it comes to how July and August have gone. And looking at the back-half guidance, with third quarter sales getting close to Q2, that's a bit under what we've typically seen on a sequential basis, and even what the guidance suggests for Q4 is somewhat below what we saw in 2018 and '19. So what I want to ask is whether there's any conservatism baked into the guidance because of a possible COVID impact. And I had one follow-up.

Adam Elsesser

executive
#16

Yes. Let me just offer a quick, general response on the trend, and then maybe Jason can address the particular guidance question and explain why — what our quarter-by-quarter implication looked like compared with the actual guidance number. On the whole, we feel extremely at ease and confident in the business. Clearly, the guidance — the number itself represents a raise that isn't insignificant, and that gives us considerable confidence. The news, which we included in the prepared remarks, that's ongoing and what's taking place. You do need to just take in the breadth for a moment. There are a handful of other details Jason can go over. But I would treat the entire range for the back half of the year as the pertinent question and that we feel exceptionally strongly about. But Jason, would you like to add a few things?

Jason Mills

executive
#17

Yeah. There are just a couple of items I want to flag. On the guidance raise, clearly we're feeling pretty good about it. And that bump is a solid step up from what we posted this quarter versus what people were expecting. So when you step back and look at how the bulk of the year has played out, things have gone pretty well throughout our business, in both Neuro and Vascular, producing growth that came in stronger than we'd anticipated. On your points or questions about the sequential picture, we did mention in the prepared remarks, as you know, the topic of elective procedures during the second quarter. Fortunately, what we observed over those three months was a rise in vaccinations across the nation, which clearly allowed hospitals to perform more elective cases. And our sense is that this likely contributed to those elective cases, or the volume on the embolization side — particularly peripheral embolization — somewhere in the range of $3.5 million to $4 million. So that gave us a lift during the quarter, and we hope it keeps going, though we have to stay mindful of where things stand right now with the Delta variant.

Larry Biegelsen

analyst
#18

That's a big help. Now regarding peripheral embolization, even if we factor in the $3 million to $4 million, possibly a catch-up, Jason, assuming that's what you meant moments ago, it was still a pretty strong quarter, Adam. So I'm wondering — based on our calculations, that's more than $40 million for the quarter, which is a record. So how do you expect that to unfold? And what's fueling the growth? Since, as you're aware, that's likely the business of yours that people understand the least.

Adam Elsesser

executive
#19

Yes. Thanks for asking that, Larry. It's a constant source of satisfaction and excitement for us to observe and be involved in that business. For some time now, we've kept innovating on the peripheral side of embolization. Over the last couple of years, we've introduced quite a few new products, among them the Ruby LP line last year; and the advantages of that technology are truly remarkable. And we've witnessed it time and again — once people begin using it, they switch over to it. The success we're experiencing. The field isn't as, shall we say, well established as one might have assumed. And there's plenty of opportunity for innovation, plus many kinds of conditions that could benefit from coil technology which previously might not have used other options but can now shift to coils, given the distinctive characteristics of our coil technology, which, as you're aware, are usually larger, softer, and simpler to deploy in numerous instances. And we're discovering that it's beginning to keep winning over new adopters; so I believe there's substantial ongoing potential to expand that business, both within the U.S., as we mentioned, and also abroad in the years to come.

Bill Plovanic

analyst
#20

To kick things off, I want to focus on the neurovascular segment. That figure is something we haven't observed since 2019; they're nearly hitting record levels; and I'm somewhat interested in how the JET 7 Xtra Flex recall played in; I dislike dredging up history. But to confirm, what stage are we at in working through it? What number of accounts do you figure you either lost or eventually regained? And basically, are we past any fallout from it, so it's more of a steady path ahead?

Adam Elsesser

executive
#21

Bill, that's an excellent query. I believe we're at the point where — the fallout from it, clearly, there was significant competitive testing as folks sought a substitute for the Xtra Flex catheter. My sense is — and what we've said backs this up. Thanks to the fresh RED series, including the fantastic early results with RED 62, plus RED 68 arriving in the next RED catheter that came somewhat later in the period, I believe we view the latter half, especially Q4, as a chance to firmly rebuild our position in stroke care. And we can't wait for it. So ongoing innovation is genuinely needed in this area. That's clear from conversations with customers. We recently enjoyed a very productive SNIS conference, the first in-person medical event I've attended in ages since COVID. And the backing we received from doctors, the enthusiasm over the fact that we keep innovating, despite the recall and all of it, was as powerful as anything I've heard in a very long time, and it gave me tremendous confidence that our approach is correct. We're headed in the right direction, and our physician clients are offering plenty of encouragement. So I'm fairly thrilled about how our stroke division will develop across roughly the next 2, 3, or 4 quarters.

Bill Plovanic

analyst
#22

All right. Then, as a follow-up, your SG&A expense rose roughly $10 million against revenue of approximately $15 million, so it looks like you're making fairly substantial forward investments. Does that involve personnel? Is it domestic, international? Any detail would be very much appreciated.

Maggie Yuen

executive
#23

Yeah. What I'd say is that in the past, we kept putting money into commercial resources, meaning our workforce. Yet simultaneously, we're seeing a lot of travel within the country and face-to-face events bounce back quickly to essentially where they stood before COVID. And the third component is that we'll keep funding G&A infrastructure so we're ready to scale.

Bob Marcus

analyst
#24

Excellent. Congratulations on a fantastic quarter. Perhaps one more question about finances. There isn't a lot to criticize regarding this quarter; however, one issue: gross margin ended up somewhat lower than what the Street had anticipated. Is there anything that's one-time in nature, or anything we ought to be aware of? And what's the right way to consider the remainder of Q3 and Q4?

Maggie Yuen

executive
#25

Yeah. I appreciate that question, Robbie. Within gross margin, there aren't any significant one-time cost charges. I believe during the prior quarter, we noted that gross margin is often able to shift somewhat based on product and mix. And what happened this quarter is simply a minor shift in certain product mix. Given the Delta variant concerns we currently have, we have no intention of eliminating any COVID safety measures and the associated cost structure that we've established. At the same time, we keep up robust productivity, and we keep putting money into our capacity too. Therefore, for the latter half of 2021, we anticipate gross margin will stay at a level comparable to what we saw in the first half of the year.

Bob Marcus

analyst
#26

All right, great. Perhaps a brief additional question. With REAL VR, it appears you have 4 or 3 versions that you're rolling out. Could you share any insight into what each one is designed for? How has the market responded thus far? And what do you believe the demand is in the field, given that reimbursement has improved and now permits remote use of this?

Adam Elsesser

executive
#27

Yeah, that's an excellent question. Rather than just telling everyone to please attend our Investor Day on September 21, I'll attempt to offer just a small amount of very broad context, since I truly don't want to take away the excitement from the team who will present in real depth. The crucial point, as you're aware, is that at the beginning we developed a product designed exclusively for a highly specific patient population. These are individuals who suffered some kind of neurological injury to the brain, usually caused by ischemic stroke, another form of injury, and who required restoration of certain physical movement, and the REAL system plus the initial application, which all of you observed at our first Investor Day, was named Happy Valley and was aimed at that; we are definitely conscious of the enormous, truly remarkable collection of clinical evidence backing the use of VR across a wide range of additional conditions. We will revisit this at the Investor Day, covering not only that fairly evident use case, but also areas like mental health, memory, depression, anxiety, and various other issues that people genuinely endure, along with the advantages of VR. So the hardware setups are genuinely designed to suit the diverse environments and categories of requirements we are addressing; and we'll cover that in more depth. We aren't yet bringing all of these to market. As I mentioned, the i-Series is merely being displayed this week at the HIMSS meeting. We'll walk through the schedule for and the strategy behind commercialization at the Investor Day one month from now as well.

Joanne Wuensch

analyst
#28

There are 2 topics I'd like to discuss or raise. First, you brought up the term symbiosis near the start of today's call, and I'd appreciate it if you could elaborate a bit on that — perhaps it's a portfolio management phrase, but some clarification would help. Then my second question concerns the RED series. I want to understand better what distinguishes these aspiration catheters from one another, and what should we expect from the third iteration of that series?

Adam Elsesser

executive
#29

Yes. Excellent question. That word — I'm fond of symbiosis. It genuinely describes how the 2 separate — or at least this is our reading of what it means, and if we've misunderstood, I apologize. But truly, the 2 separate sides of our company across neuro and vascular, meaning the coil business alongside the thrombectomy business, which address different conditions, how those franchises, those product lines have functioned out in the field alongside our customers. How a win in one area has unlocked possibilities in the other. How innovation on one front has generated interest among physicians toward the remainder of our portfolio. And it's genuinely been extraordinary and, in my view, about as pure as it gets, which is the — when we bring the company and our products to new physicians unfamiliar with the performance of — simply the raw clinical performance and usefulness of our products on one side, that opens interest in and access to the rest of our business. So that's the meaning behind it. Regarding the RED series, RED 62, as we've mentioned, is an entirely new catheter, specifically dimensioned to address usually more distal clots, a space where we believe there's room for greater innovation, where more innovation is needed. The response to this product has been extremely, extremely positive thus far. To begin with, its trackability is performing very well. We're also hearing about some users deploying it in more proximal spots such as the M1, which strikes me as proof of its trackability and its capacity to keep its shape while you aspirate through it. RED 68 clearly is the size of — RED 68 matches the workhorse product that served for many years, the ACE68. We've simply enhanced that catheter's trackability nicely; and then the following one on the way, we haven't formally announced or discussed it, but we certainly will <<inaudible>> cleared and look forward to bringing that to market too. So really, the aim behind all these catheters remains what it has always been: trackability comes first, since you can't accomplish much until you can get it there easily, and then comes its capacity to maintain shape and safely, effectively aspirate clot out.

Margaret Kaczor

analyst
#30

I wanted to ask a follow-up about vascular. My understanding is that you've mentioned doctors are more and more using single-session therapy, so I was wondering whether you see that as a wider market shift. And is it caused by something you're doing, or is it something specific to your company? What I'm getting at is whether physicians are simply saying, in general, I understand this. I'm present, I'm prepared to proceed; meaning this is just genuine market adoption, or is it still somewhat early, where they need to observe several cases and have more patients coming through?

Adam Elsesser

executive
#31

Yes. I believe that's a truly excellent question. I would still describe us as being in early stages; it's beginning to occur. That phrase, for instance, is now in circulation. Twelve months ago, 18 months ago, nobody would have described the objective as performing single-session thrombectomy. So the mere fact that we employ that phrase, that you employ that phrase, it has become quite clear that this is a deliberate aim that is not — that is positive. And for me, that's a wonderful indicator for the field. And I believe many other businesses are chasing this. I think that has been extremely valuable for the field, in contrast to certain areas where the field is crowded and competitive in a bad way in other markets. This is — it's so big and so under-tapped, I think it has been quite advantageous to have companies all kind of aligned on the objective. And then physicians begin to move in that direction. The finest technology will eventually prevail. And clearly, we feel quite sure that with this present version and upcoming versions, we will remain in a very strong position; but I still believe we are in the early stages. We still have the vast, vast majority of suitable patients or eligible patients still not receiving single-session therapy. And they are receiving multiple-day dripping of tPA. And that means we have plenty of work in the years ahead. But it feels like the conversation, from hearing what the field is saying, you can now have it. There's some open-mindedness, at least at the start. So I think there's the start of momentum. How long it will take, how much effort it will require, I think we're facing years of work, not months of work, but it feels like we've turned a bit of a corner here.

Margaret Kaczor

analyst
#32

Alright, so perhaps we can push on that point a bit more. When it comes to some of those accounts you're already present in, would you say clinicians might be picking out particular patients themselves, whether based on risk profile or indication, and is that how you're observing uptake out in the field?

Adam Elsesser

executive
#33

I'm not certain I can respond to that with the level of precision the question calls for. I'm sure there are doctors who still do a mix of both. I'm not familiar with those individuals, but I don't want to claim they aren't — that wouldn't be accurate; that strikes me as entirely possible. Without a doubt, the clients who account for the majority of our present revenue are largely folks who have more or less made that shift and have faith in it and have faith in what the technology can deliver, and as a result they're applying it across all or nearly all of their cases.

Jee Hamlyn-Harris

executive
#34

Thanks, operator. Our management team and I want to express our appreciation once more for everyone being here with us today and for the attention you're giving Penumbra. We're eager to bring you up to speed during this call covering our third quarter.

Operator

operator
#35

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.